Posts on Jan 1970

TODAY: NANBIOSIS to Participate in CIBEROBN Webinar on Translational Biomedicine

NANBIOSIS will participate online this afternoon, September 17, 2026, at 4:00 p.m., in the CIBEROBN Webinars 2026 session “Translational Biomedicine: Disease Mechanisms and Advanced Research Infrastructures.” The webinar is part of the programme organised by the Spanish Biomedical Research Network (CIBEROBN).

The session will focus on “Intestinal proteases in the spotlight: drivers of alcohol-associated liver disease progression”, addressing current research into disease mechanisms and translational biomedicine.

The webinar will also feature an introduction to NANBIOSIS, presented by Gabriel Alfranca, Communication and Internationalization Manager of CIBER-BBN and NANBIOSIS. The presentation will introduce NANBIOSIS as an advanced biomedical research infrastructure supporting research and innovation in areas including nanomedicine, biomaterials and bioengineering.

The event will provide an opportunity to present NANBIOSIS to researchers and other professionals interested in translational biomedical research and advanced research infrastructures.

Date: September 17, 2026
Time: 4:00 p.m.
Format: Online
Programme: CIBEROBN Webinars 2026

JOIN THE WEBINAR HERE

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: